Bull and Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the asymmetry on management's own reaffirmed FY26 EBITDA guide is real, but the decisive proving event (Q1 FY2026 earnings) lands inside a two-week window and resolves the single live tension on its own. Both advocates agree the consolidated subscriber arithmetic is the load-bearing question; they disagree on whether Clinical's 42% growth can offset the Behavioral melt fast enough to clear a $105–115M EBITDA bar. Bull's strongest piece of independent evidence — Brigade's Carney Hawks paying $22.14 in the open market on November 19, 2025 — is hard to fade and indicates the most informed marginal buyer is anchored at more than 2x today's $9.80 print. Bear's strongest argument — six straight years of declining operating cash flow and Behavioral subscribers shedding 250–400K/year against a 130K Clinical base — is structural and not refuted by the balance-sheet reset. The clean trade is to wait two weeks: Q1 will either confirm the Clinical ramp inside the FY26 guide envelope, or cut it.

Bull Case

Bull's price target, method, timeline, disconfirming signal. $22 over a 12–18 month horizon, derived as 6x EV/EBITDA on FY26 mid-guide EBITDA of $110M ($660M EV less $300M net debt = $360M equity over ~11M fully-diluted post-MIP shares ≈ $33, haircut to $22 for working-capital drag, residual amortization, and Clinical execution risk). Primary catalyst is the Q1 FY2026 print, expected late April / early May 2026 — within two weeks of today. Disconfirming signal: two consecutive quarters of Behavioral declining ≥15% YoY and Clinical below 160K at mid-FY26.

Bear Case

Bear's downside target, method, timeline, cover signal. $4.00 per share (≈ −59% from $9.80) on a 12-month horizon, derived as 5x EV/EBITDA on $70M FY26 EBITDA (haircut ~$40M from management's mid-guide for ~$20M of recurring restructuring add-back and ~$20M of Behavioral attrition vs guide): $70M × 5x = $350M EV, less $308M net debt = $42M equity over ~10M post-emergence shares ≈ $4.20. Primary trigger: Q1 FY26 earnings (early-mid May 2026) showing Clinical below 160K and Behavioral attrition unchanged or accelerating, forcing sell-side EBITDA cuts toward $80M and likely an interim intangibles impairment by Q2/Q3 FY26 against the freshly written-up $529M base. Cover signal: Clinical crossing 200K with Behavioral net adds breakeven for two consecutive quarters and operating cash flow turning positive.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. Bull narrowly carries more weight because management's own FY26 guide already prices the Behavioral melt at −13% revenue, and the marginal informed buyer (Brigade's Hawks at $22.14) has staked cash on the post-emergence structure — two empirical anchors that are independent of any narrative. The single most important tension is whether the reaffirmed $105–115M EBITDA guide is achievable; everything else flows from it. Bear could still be right because the consolidated subscriber arithmetic is genuinely structural — six straight years of declining OCF and a Clinical base too small to mathematically offset the Behavioral run-rate decline are not refuted by the balance-sheet reset, and a Q2/Q3 FY26 interim impairment against the $529M intangibles base remains a live re-pricing event. The decisive evidence lands inside two weeks: Q1 FY2026 earnings, with Clinical subscriber count and EBITDA run-rate as the legible scoreboard. The verdict flips to Lean Long if Q1 prints Clinical tracking toward 200K and FY26 EBITDA holds inside the $105–115M envelope; it flips to Avoid if Clinical comes in below 160K with sell-side cutting toward $80M. The institutional move is to let the print decide, then size — not to commit ahead of evidence that arrives this fast.